Erschienen in:
01.02.2011 | Case Report
Benefit and a possible risk of tocilizumab therapy for adult-onset Still’s disease accompanied by macrophage-activation syndrome
verfasst von:
Masafumi Kobayashi, Yuko Takahashi, Hiroyuki Yamashita, Hiroshi Kaneko, Akio Mimori
Erschienen in:
Modern Rheumatology
|
Ausgabe 1/2011
Einloggen, um Zugang zu erhalten
Abstract
We report a 57-year-old female case of intractable adult-onset Still’s disease (AOSD). Initial high-dose prednisolone therapy was ineffective, and macrophage-activation syndrome (MAS) manifested after one session of additional tocilizumab therapy. After successful treatment for MAS with lipo-dexamethasone and cyclosporin, tocilizumab therapy aided in the rapid reduction of the therapeutic steroid dose. Tocilizumab may be useful for maintenance therapy for AOSD, although its efficacy is unclear for the highly active phase of the disease.